Philip Romm, MD
Interventional Cardiology · Lawrenceville, GANPI 1760478184
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Abbott at 54.8% of the total. 2025 is the largest year on record at $26,598, 2.6 times the $10,321 reported in 2019.
Across 481 payments — averaging $107.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$28K
- Amgen$9K
- Boston Scientific$6K
- Penumbra, Inc.$3K
- Johnson & Johnson$635
- Novartis$592
- plus $4K from 30 others
What the payments were for
- Consulting fees$21,15041%
- Speaking & faculty fees$7,20014%
- Travel & lodging$9,52618%
- Food & beverage$13,90927%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 57 | $28,387 |
| Amgen | 64 | $8,606 |
| Boston Scientific | 68 | $6,483 |
| Penumbra, Inc. | 7 | $2,712 |
| Johnson & Johnson | 40 | $635 |
| Novartis | 33 | $592 |
| Pfizer | 26 | $475 |
| Amarin Pharma, Inc. | 27 | $389 |
| Esperion Therapeutics, Inc. | 22 | $377 |
| E.r. Squibb & Sons, L.L.C. | 18 | $330 |
| Abiomed | 10 | $302 |
| Boehringer Ingelheim | 12 | $253 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $237 |
| AstraZeneca | 13 | $227 |
| Sanofi-aventis U.S. LLC | 13 | $225 |
| Shockwave Medical, Inc | 4 | $214 |
| Inari Medical, Inc. | 1 | $199 |
| Angiodynamics, Inc. | 2 | $199 |
| Bayer | 5 | $132 |
| Edwards Lifesciences | 3 | $131 |
| Merck | 6 | $115 |
| Regeneron Healthcare Solutions, Inc. | 5 | $109 |
| W. L. Gore & Associates, Inc. | 4 | $107 |
| Arbor Pharmaceuticals, Inc. | 5 | $64 |
| Chiesi USA, Inc. | 3 | $50 |
| Heartflow, Inc. | 2 | $45 |
| Medtronic | 3 | $40 |
| Novo Nordisk | 2 | $35 |
| Lundbeck LLC | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Gilead | 2 | $29 |
| Scpharmaceuticals Inc. | 1 | $22 |
| GSK | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Baylis Medical Company Inc | 1 | $12 |
| Aegerion Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$20,417
- Repatha$7,761
- ENSITE PRECISION$5,106
- Indigo System$2,675
- Watchman$1,842
- VersaCross Access Solution$1,302
- AMPLATZER$1,262
- AVVIGO Guidance System$260
- SYNERGY$255
- GENERAL - STENTS$214
- FLOWTRIEVER CATHETER, S$199
- CT THROMBECTOMY SYSTEM KIT$199
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$163
- SUPERA$163
- AlphaVac$151
- WATCHMAN FLX$149
- CARDIOMEMS$142
- Absolute Pro vascular stent system$137
- WATCHMAN Access System$132
- Impella$125
How this compares
$51,839 in reported general payments places this provider in the 85th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 628 | $802,214 |
| XareltoRivaroxaban | 200 | $256,920 |
| EntrestoSacubitril/Valsartan | 200 | $238,295 |
| Repatha SureclickEvolocumab | 150 | $134,192 |
| FarxigaDapagliflozin Propanediol | 119 | $125,779 |
| CamzyosMavacamten | 12 | $96,214 |
| BrilintaTicagrelor | 70 | $67,358 |
| Praluent PenAlirocumab | 65 | $65,861 |
| VascepaIcosapent Ethyl | 70 | $53,136 |
| JardianceEmpagliflozin | 34 | $42,873 |
| MultaqDronedarone Hcl | 23 | $32,862 |
| NexletolBempedoic Acid | 37 | $26,546 |
| Valsartan | 736 | $20,036 |
| Metoprolol Succinate | 1,252 | $15,200 |
| Ezetimibe | 767 | $15,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $475 | $802,214628 claims |
| Johnson & JohnsonXarelto | $635 | $256,920200 claims |
| NovartisEntresto | $592 | $238,295200 claims |
| AstraZenecaFarxiga, Brilinta | $227 | $193,137189 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $330 | $96,21412 claims |
| Boehringer IngelheimJardiance | $253 | $42,87334 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $377 | $37,82250 claims |
| Sanofi-aventis U.S. LLCMultaq | $225 | $32,86223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Lawrenceville
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
- Katherine KunkelAtlanta$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.